Hematology

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

The move emphasizes the need for vigilant monitoring.

Medicaid expansion enhances 5-year cancer survival rates in rural and high-poverty areas, highlighting the importance of financial support for better health outcomes.

Frail patients with multiple myeloma (MM) can safely reduce dexamethasone use, enhancing treatment outcomes without increasing infection risks.

Oncology pharmacists advance multiple myeloma care with BCMA bispecifics and CAR T-cell therapy, improving safety, logistics, and outcomes for American Pharmacist Month.

Gene therapy offers transformative potential in treating diseases like sickle cell and leukemia, highlighting pharmacists' crucial roles.

Gene therapy revolutionizes treatment in oncology, highlighting pharmacists' vital roles in patient care and long-term monitoring.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

Mary Nauffal, PharmD, MS, BCOP, discusses innovative use of isatuximab for red cell aplasia post stem cell transplant, highlighting its potential in clinical trials.

Etentamig shows promise in managing infections for relapsed/refractory multiple myeloma.

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

Xavier Leleu, MD, PhD, shares how OBI technology reduces preparation time and manual pushes for pharmacists.

Expert shares the evolving role of pharmacy in patient care, emphasizing treatment accessibility and monitoring.

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.

Pharmacists navigate the evolving hematology-oncology landscape, utilizing genetic insights and innovative therapies to enhance patient care.

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Expert shares the promising potential of linvoseltamab in treating high-risk smoldering multiple myeloma.

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Expert discusses groundbreaking studies on the on-body injector for isatuximab, highlighting its efficacy, safety, and patient convenience.

Pharmacists enhance patient care in multiple myeloma by focusing on infection prevention, CRS management, and optimizing outcomes with T-cell engagers post-CAR T.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.

Costimulatory bispecific antibodies revolutionize multiple myeloma treatment, offering deeper responses and flexible sequencing strategies for patients.

New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed/refractory multiple myeloma.